#1 Clinical Trials Search in Europe

Dabigatran Etexilate

Dabigatran etexilate, also known by the brand name Pradaxa, is an anticoagulant medication that has been the subject of numerous clinical trials. These studies aim to evaluate its safety and effectiveness in preventing blood clots and reducing the risk of stroke in patients with various conditions, including atrial fibrillation, kidney disease, and after knee replacement surgery. The trials explore different dosages, compare dabigatran to other anticoagulants like warfarin, and assess its impact on kidney function and bleeding risks.

Table of Contents

What is Dabigatran Etexilate?

Dabigatran etexilate is an oral anticoagulant medication, also known as a “blood thinner”. It is sold under the brand name Pradaxa[1]. Dabigatran etexilate works by preventing blood clots from forming in your body[2].

What is Dabigatran Etexilate Used For?

Dabigatran etexilate is primarily used to prevent and treat several conditions related to blood clots:

  • Atrial Fibrillation: It helps prevent stroke and blood clots in people with a heart rhythm disorder called atrial fibrillation[3].
  • Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE): It’s used to treat and prevent these types of blood clots that can form in the legs or lungs[4].
  • Prevention after Surgery: It’s used to prevent blood clots in patients who have had hip or knee replacement surgery[5].

How Does Dabigatran Etexilate Work?

Dabigatran etexilate is a direct thrombin inhibitor. This means it works by blocking the action of a substance in your body called thrombin. Thrombin is a key component in the formation of blood clots. By inhibiting thrombin, dabigatran etexilate helps prevent unwanted blood clots from forming[2].

Dosage and Administration

Dabigatran etexilate is typically taken orally in capsule form. The dosage can vary depending on the condition being treated and individual patient factors:

  • For atrial fibrillation, common doses are 150 mg twice daily or 110 mg twice daily[3].
  • For prevention after surgery, a dose of 220 mg once daily may be used[5].
  • The dose may be adjusted based on kidney function or other factors[6].

It’s important to take dabigatran etexilate exactly as prescribed by your doctor. Do not stop taking it without consulting your healthcare provider, as this could increase your risk of blood clots[2].

Side Effects and Safety

Like all medications, dabigatran etexilate can cause side effects. The most common and important side effect to be aware of is bleeding. This can include:

  • Major bleeding: This includes severe or life-threatening bleeding events[7].
  • Clinically relevant bleeding: This includes less severe bleeding that still requires medical attention[7].
  • Minor bleeding: This includes minor cuts that may bleed longer than usual, nosebleeds, or bruising more easily[7].

Other potential side effects can include digestive system issues like indigestion or stomach pain. If you experience any unusual symptoms or bleeding while taking dabigatran etexilate, contact your healthcare provider immediately[2].

Drug Interactions

Dabigatran etexilate can interact with other medications. It’s important to tell your doctor about all medications you’re taking, including over-the-counter drugs and supplements. Some key interactions to be aware of include:

  • Other blood thinners or medications that affect blood clotting
  • Certain heart medications
  • Some antibiotics
  • Some antifungal medications

These interactions can affect how dabigatran etexilate works or increase the risk of side effects[2].

Use in Special Populations

Dabigatran etexilate may need to be used with caution or at adjusted doses in certain groups of people:

  • Kidney Problems: The dose may need to be adjusted in people with kidney disease[6].
  • Elderly Patients: Older adults may be at higher risk of bleeding and may need closer monitoring[2].
  • Pregnancy and Breastfeeding: The safety of dabigatran etexilate during pregnancy and breastfeeding is not well established. Always consult with your doctor if you’re pregnant, planning to become pregnant, or breastfeeding[2].

Ongoing Research

Researchers continue to study dabigatran etexilate to better understand its effects and potential uses. Some areas of ongoing research include:

  • Its use in patients with both atrial fibrillation and kidney disease[8].
  • Comparing its effectiveness to other blood thinners in various conditions[3].
  • Studying its long-term effects on kidney function[8].
  • Investigating its use in preventing blood clots in patients with coronary artery disease[7].

These ongoing studies help doctors and patients better understand how to use dabigatran etexilate safely and effectively[2].

Aspect Details
Main Indications Prevention of stroke in atrial fibrillation, prevention of venous thromboembolism after knee replacement surgery
Dosages Studied 75 mg, 110 mg, 150 mg, 220 mg, 300 mg (various dosing schedules)
Comparator Drugs Warfarin, placebo
Key Outcome Measures Stroke rates, bleeding events, venous thromboembolism, changes in kidney function
Safety Considerations Bleeding risk, effects on liver function, use in patients with kidney disease
Special Populations Patients with chronic kidney disease, patients undergoing dialysis, patients with diabetes
Pharmacokinetic Assessments Plasma concentration, area under the curve, maximum concentration
Pharmacodynamic Assessments aPTT, ECT, INR

FAQ

  • What is dabigatran etexilate used for? Dabigatran etexilate is primarily used to prevent blood clots and reduce the risk of stroke in patients with atrial fibrillation. It's also been studied for use after knee replacement surgery and in patients with chronic kidney disease.
  • How does dabigatran etexilate compare to warfarin? Several trials have compared dabigatran etexilate to warfarin. These studies typically look at factors such as efficacy in preventing strokes, bleeding risks, and effects on kidney function. Some evidence suggests dabigatran may have advantages over warfarin in certain patient groups.
  • What are the main side effects of dabigatran etexilate? The main side effect of concern with dabigatran etexilate is bleeding. Clinical trials have closely monitored for major bleeding events, clinically relevant bleeding, and minor bleeding. Other potential side effects include gastrointestinal issues and changes in liver function tests.
  • Can dabigatran etexilate be used in patients with kidney problems? Yes, but with caution. Several trials have specifically looked at the use of dabigatran etexilate in patients with chronic kidney disease. The dosage may need to be adjusted based on kidney function, and some studies have examined how the drug affects kidney function over time.
  • How is the effectiveness of dabigatran etexilate measured in clinical trials? Effectiveness is often measured by looking at rates of blood clots, strokes, and other cardiovascular events. Trials also examine blood tests that measure clotting ability, such as activated partial thromboplastin time (aPTT) and ecarin clotting time (ECT).

Ongoing Clinical Trials on Dabigatran Etexilate

  • Study on Preventing Blood Clots in Patients with New-Onset Post-Operative Atrial Fibrillation after CABG Using Apixaban and Drug Combination

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study of dabigatran, apixaban and edoxaban for prevention of stroke recurrence in patients with acute ischemic stroke without known atrial fibrillation

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Greece Spain

  • Study Comparing Dabigatran Etexilate, Acetylsalicylic Acid, and Clopidogrel for Preventing Blood Clots in Patients with Atrial Fibrillation After Heart Procedure

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Safety and Effectiveness of Apixaban, Edoxaban, and Phenprocoumon for Patients with Chronic Thromboembolic Pulmonary Hypertension Undergoing Balloon Pulmonary Angioplasty

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on How Elinzanetant Affects Dabigatran Etexilate in Healthy Volunteers with Vasomotor Symptoms

    Not recruiting

    1 1 1
    Investigated drugs:
    Germany

  • Study on the Effects of Apixaban, Acetylsalicylic Acid, and Rivaroxaban on Heart Valve Thickening in Patients with Aortic Valve Replacement

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Denmark

  • Study on Dabigatran and Phenprocoumon for Treating Left Ventricular Thrombosis After Heart Attack in Patients with STEMI

    Not recruiting

    1 1 1
    Investigated drugs:
    Austria

  • Study on Dabigatran, Apixaban, Rivaroxaban, and Edoxaban for Patients with Atrial Fibrillation, Deep Vein Thrombosis, or Pulmonary Embolism

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

Glossary

  • Atrial Fibrillation: An irregular and often rapid heart rate that can increase the risk of stroke and other heart-related complications.
  • Chronic Kidney Disease (CKD): A condition characterized by gradual loss of kidney function over time.
  • Venous Thromboembolism (VTE): A condition where blood clots form in the veins, typically in the legs or lungs.
  • Stroke: A medical condition where poor blood flow to the brain results in cell death, potentially causing lasting brain damage.
  • International Normalized Ratio (INR): A laboratory test used to check how long it takes blood to form a clot, often used to monitor warfarin therapy.
  • Activated Partial Thromboplastin Time (aPTT): A blood test that measures how long it takes for blood to clot, used to monitor anticoagulant therapy.
  • Ecarin Clotting Time (ECT): A blood test used to measure the anticoagulant effect of direct thrombin inhibitors like dabigatran.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Pharmacodynamics: The study of the biochemical and physiological effects of drugs on the body.
  • Major Bleeding: Serious bleeding events that may require medical intervention or hospitalization.
  • Clinically Relevant Bleeding: Bleeding events that, while not major, are still significant enough to impact patient care or quality of life.
  • eGFR: Estimated Glomerular Filtration Rate, a test used to measure kidney function.

References

  1. https://clinicaltrials.gov/study/NCT01136408
  2. https://clinicaltrials.gov/study/NCT05673889
  3. https://clinicaltrials.gov/study/NCT00157248
  4. https://clinicaltrials.gov/study/NCT01976507
  5. https://clinicaltrials.gov/study/NCT00246025
  6. https://clinicaltrials.gov/study/NCT01241539
  7. https://clinicaltrials.gov/study/NCT00621855
  8. https://clinicaltrials.gov/study/NCT03789695